Nonmyeloblative stem cell transplantation (NST, SCT) aims to induce host-versus-graft tolerance for subsequent immunotherapy of underlying disease with alloreactive donor lymphocytes, focusing on well-tolerated conditioning suitable for elderly individuals or for other risk factors. However, there is a subset of high-risk patients who cannot tolerate NST. A new protocol consisting of fludarabine 30 mg/m 2 Â 6 days (days À8 to -2), very-lowdose busulfan (2 mg/kg Â 2 days, days À6 to -5), without anti thymocyte globulin (ATG), was employed in 11 highrisk patients aged 26-58 years. Graft-versus-host-disease (GVHD) prophylaxis consisted of low-dose and shortcourse cyclosporine-A (CSA) alone. One patient died during the nadir due to pulmonary complications. Other patients showed rapid three-lineage engraftment, without complete aplasia; 6/10 patients did not require platelet transfusion and 8/10 had full donor chimerism without transient mixed chimerism. Owing to intentional selection of highly poor-risk patients, overall mortality was high and only one patient survived. Acute GVHD (Xgrade I) occurred in 8/10 evaluable patients, 5/8 while off CSA; 5/8 developed grade III-IV acute GVHD. It appears that our modified, minimally ablative stem cell transplantation (MST) may be used for high-risk patients in need of allo-SCT. Furthermore, although the MST conditioning is not myeloablative, it results in myeloablation of the host hematopoietic system, mediated by alloreactive lymphocytes. Bone Marrow Transplantation (2003) 32, 557-561. doi:10.1038/sj.bmt.1704190 Keywords: allogeneic stem cell transplantation; reduced intensity conditioning; nonmyeloablative stem cell transplantation (NST); high-risk patients; leukemia; hematologic malignancies Allogeneic bone marrow transplantation (BMT) from a fully matched donor is the treatment of choice for a growing number of clinical indications. The nonmyeloblative stem cell transplantation (NST) protocol was developed with the goal of inducing host-versus-graft transplantation tolerance with fast engraftment of donor stem cells and immunocompetent lymphocytes with well-tolerated conditioning that could also be used in elderly individuals and other high-risk patients in need of BMT normally excluded from conventional transplantation programs. The rationale behind the NST strategy is to focus on optimal induction of graft-versus-leukemia (GVL) effects for the elimination of all malignant cells by alloreactive immunocompetent lymphocytes (T cells, not excluding natural killer (NK) and natural killer T cells (NKT cells)) obtained from a matched donor (sibling or matched unrelated donor) as an alternative to standard hazardous high-dose myeloablative chemoradiotherapy.
intensity conditioning; nonmyeloablative stem cell transplantation (NST); high-risk patients; leukemia; hematologic malignancies Allogeneic bone marrow transplantation (BMT) from a fully matched donor is the treatment of choice for a growing number of clinical indications. The nonmyeloblative stem cell transplantation (NST) protocol was developed with the goal of inducing host-versus-graft transplantation tolerance with fast engraftment of donor stem cells and immunocompetent lymphocytes with well-tolerated conditioning that could also be used in elderly individuals and other high-risk patients in need of BMT normally excluded from conventional transplantation programs. The rationale behind the NST strategy is to focus on optimal induction of graft-versus-leukemia (GVL) effects for the elimination of all malignant cells by alloreactive immunocompetent lymphocytes (T cells, not excluding natural killer (NK) and natural killer T cells (NKT cells)) obtained from a matched donor (sibling or matched unrelated donor) as an alternative to standard hazardous high-dose myeloablative chemoradiotherapy. [1] [2] [3] The beneficial role of donor lymphocyte infusion (DLI) following induction of host-versus-graft transplantation tolerance that results from engraftment of donor hematopoietic stem cells has been previously documented. 4, 5 However, there is a group of patients in need of transplantation who may not be able to tolerate even the standard NST protocol (eg intravenous (i.v.) fludarabine 30 mg/m 2 /day Â 6 days, oral busulfan 4 mg/kg/day Â 2 days and ATG (Fresenius) at a dose of 5-10 mg/kg/day Â 4) 1 due to extremely poor performance status or other risk factors.
The present report summarizes our cumulative experience in a cohort of 11 patients subjected to a milder form of the NST protocol, minimally ablative stem cell transplantation (MST), confirming that consistent engraftment of compatible mobilized blood stem cells can be accomplished with fludarabine-induced immunosuppression in parallel with minimally ablative conditioning, thus making it possible for patients in third-world countries and patients at very high risk due to poor performance status to be eligible and possible benefit from BMT.
Patients and methods
A total of 11 consecutive high-risk patients with hematologic malignancies and metastatic solid tumors not eligible for NST were enrolled in this pilot study that aimed to investigate the feasibility of inducing transplantation tolerance and durable engraftment of HLA-matched allografts. Indications for transplantation and disease status are shown in Table 1 . Patients were included if they had an indication for transplantation but their ability to survive the standard NST protocol was judged to be low (eg active life threatening infectious disease, other systemic life threatening disease metastasis, low Karnovsky performance status score (PSS) or severe psychiatric disorder), and thay had agreed to participate in the clinical trial. There were six males and five females, ranging in age from 26 to 58 (median 44) years ( Table 1 Table 2 . Prior to transplantation, all patients received trimethoprim/sulfamethoxazole (10 mg/kg/day trimethoprim) on days À8 to À2, acyclovir (500 mg/m 2 Â 3/day) from days À8 until day +100 and allopurinol (300 mg/day) on days À8 to À1. Administration of trimethoprim/sulfamethoxazole (twice weekly) was reinstituted after recovery from neutropenia, as a preventive measure against Pneumocystis carinii infection. Cytomegavirus (CMV) infections (diagnosed by two successive positive PCRs or one positive CMV pp65 antigenemia) were treated with ganciclovir 10 mg/kg/ day.
Graft-vs-host disease (GVHD) prophylaxis consisted of single-drug low-dose, short-term cyclosporine (CSA) 3 mg/ kg i.v. daily in two divided doses starting on day -4. Once the patients were mobile, CSA was administered orally. CSA dosage was tapered during the second or third month post-transplant, according to chimeric status and evidence of GVHD.
Neutropenic patients with culture-negative fever received a combination of gentamicin, cefazolin and mezlocillin, as first-line antibiotic protocol. Persisting fever was treated with amikacin and tazocin as second-line protocol, while meropenem and vancomycin were used as the third-line protocol. In cases of persistent fever not responding to antibiotic therapy within 5 days, amphotericin B (1 mg/kg every other day) was added until neutropenia resolved.
Starting on day À8 a DNA-PCR test, and later during the study period a pp65 antigenemia test were carried out weekly to detect CMV. Two consecutive positive PCR results or one antigenemia with more than one cell positive for pp65 served as an indication for replacing acyclovir with ganciclovir until a minimum of two negative tests were obtained. Patients were treated in reverse isolation rooms equipped with HEPA filters, and received a regular diet. Additional supportive measures, such as parenteral nutrition and blood component transfusion, were administered as necessary.
Acute and chronic GVHD were graded according to the International Bone Marrow Transplantation Registry (IBMTR) severity indices. 6 Immediately upon the appearance of signs and symptoms of GVHD, i.v. methylprednisolone (2 mg/kg) and CSA were administered.
In order to assess engraftment, degree of chimerism, minimal residual disease and early relapse, patients were monitored at regular intervals by cytogenetic analysis, and by donor and host-specific DNA markers, using male and female amelogenin gene PCR bands, 7 and by variable number of tandem repeat (VNTR)-PCR assay. 8 
Results
The protocol used for conditioning was well tolerated by 10 patients. One patient (UPN 1625) died during the nadir (day +9) due to continuing pulmonary complications in addition to pre-existing massive involvement of both lungs with progressive resistant Hodgkin's disease. All other patients were fully mobile at the time of the conditioning. Severe oral mucositis was absent and most of the patients were maintained on normal oral intake; only 4/11 (36%) patients required supplemental parenteral nutrition due to a low basic nutritional state aggravated by mucositis. Moderate or severe hepatic veno-occlusive disease (VOD) did not occur in any of the patients. Fever was noted in 8/11 (73%) patients (median of febrile episodes 1, range 0-2) with a median of one febrile day (range 0-20 days). None of the patients had CMV disease.
Engraftment following MST
All 10 evaluable patients displayed evidence of engraftment shortly after transplant ( Figure 1 ) and none exhibited immune-mediated rejection. Mixed chimerism was detected in two patients, one responded to withdrawal of CSA and the second patient received DLI but died soon afterwards from relapse of his underlying malignancy. In the other eight patients, rapid engraftment of donor cells with full donor chimerism was confirmed (without evidence of transient mixed chimerism). In 9/10 evaluable patients, the white blood cell count (WBC) remained above 0.1 Â 10 9 /l, and neutrophils were observed in the blood Overall survival. Owing to intentional selection of the worst poor-risk patients for a pilot study trial testing the feasibility of engraftment using a new protocol, mortality rate was very high and only one patient survived (UPN 1584, follow-up 19 months). Causes of death included basic bulky and resistant disease progression in 8/11 patients, median time to death 79.5 days (range 9-240 days). Three of these patients had both disease progression and active GVHD at the time of death. One patient died from GVHD and infection (39 days post transplantation). One patient died from sepsis (256 days post transplantation, free of his underlying malignancy with cGVHD) and one from the combination of underlying malignancy progression and GVHD (included in the underlying malignancy progression patients mentioned above, 240 days post transplantation).
Incidence and severity of GVHD. Acute GVHD (Xgrade I) occurred in 8/10 evaluable patients; five of these patients developed grade III-IV acute GVHD. In five of the acute GVHD patients, it appeared off CSA. In three patients, acute GVHD progressed to chronic GVHD. As mentioned above, GVHD-related mortality occurred in two patients.
Discussion
Conventional myeloablative BMT is a high-risk procedure even in patients in excellent general condition. Our previous reports as well as data obtained from other transplant centers confirm that procedure-related toxicity and mortality may be reduced by using nonmyeloablative or reduced intensity conditioning prior to transplantation of allogeneic stem cells.
1,2,9-12 Although reduced intensity protocols decrease the rate and severity of transplantrelated complications as indicated in recent literature, [9] [10] [11] [12] there is a subset of patients who may not be in a condition to tolerate the conditioning required for NST. Based on previous observations featuring the efficacy of DLI to eliminate tumor cells resistant to maximally tolerated doses of chemoradiotherapy with no additional cytoreduction following induction of host-versus-graft transplantation tolerance, it seemed reasonable to attempt to treat patients with resistant malignancies with allogeneic lymphocytes following minimally ablative conditioning, by attempting to further minimize the intensity of myeloablation. On the other hand, due to hematopoietic competition, further reduction of transplant conditioning may be associated with an increased risk of rejection or nonengraftment. Our Table 2 Mobilized blood stem cells used for transplantation on days 0 and +1 data, based on a cohort of 10 evaluable patients, suggests that durable engraftment of fully matched HLA allografts may be attained with minimal nonmyeloablative conditioning with an extremely low procedure-related toxicity. This may be acceptable by any patient in need. The high donor CD34+ cell numbers infused (Table 2) may have contributed to the high rate of donor chimerism. Considering the severity of the clinical condition in view of the advanced bulky and resistant diseases in this cohort, little can be said about the feasibility of curing patients with less-advanced disease following successful induction of durable engraftment, since, after all, such patients are not expected to be cured even following myeloablative BMT. Nonetheless, based on our study, it seems reasonable to assume that engraftment of stem cells from a fully HLAmatched donor can be accomplished on an outpatient basis, while minimizing early marrow aplasia and the need for frequent transfusions of blood products, and prolonged intravenous antibiotic therapy, thus reducing transplantrelated complications. Adopting the aforementioned principles, we assume that a transplant procedure may be successfully accomplished for any patient in need with a matched donor available, although transplant-related complications, particularly acute GVHD, attributable to the exclusion of ATG or to post transplant persistence of donor cells, might still impede transplant outcome.
Fludarabine, the common denominator in recent NST protocols, used for prevention of graft rejection, was the main immunosuppressive agent used in this protocol. This drug induces apoptosis of the lymphocyte series. Furthermore, fludarabine in combination with alkylating agents such as busulfan, 1,10 cytoxan, 11,13 melphalan 3,9 or total body irradiation (TBI) 12, 14 has proven useful for conditioning. Taken together, our observations justify the use of MST for patients in need of transplantation, regardless of age, performance status or other major risk factors who would not normally qualify for standard BMT or even NST, especially those with minimal residual disease that may be conceptually cured by alloreactive lymphocytes. Although prospective randomized studies of conventional allo-SCT vs NST have not yet been carried out, there seem to be no conclusive data to suggest that more aggressive preparatory regimens are superior in any disease category where BMT is indicated. 15, 16 Moreover, the high incidence of relapse in recipients of T cell-depleted allografts following myeloablative conditioning, 17 as well as in patients transplanted after myeloablative conditioning with no GVHD, [17] [18] [19] or recipients of allografts from an identical twin, [18] [19] [20] supports the major role played by alloreactive donor T cells in BMT, particularly at the stage of minimal residual disease.
Based on the data presented, and considering cumulative international experience, it appears that future development of less aggressive conditioning for improving the outcome of high-risk patients is fully justified. Such safer strategies should focus on more selective, effective biologic tools rather than aggressive and hazardous nonspecific cytotoreductive agents. Based on recent data, 2 it appears reasonable to assume that following induction of hostversus-graft unresponsiveness, the efficacy of GVL, or in more general terms, graft-versus-tumor (GVT) effects, may be maximized by using reactive rather than naive lymphocytes, using lymphocytes activated nonspecifically with rIL-2, as shown in mice 21, 22 and man, 5 or preferably specifically immune donor lymphocytes, as recently documented in mice [23] [24] [25] and man. 26 Thus, we anticipate that using immune DLI in conjunction with MST, immunotherapy may provide an ultimately safe, cost-effective and efficient modality for treatment of patients resistant to conventional anticancer therapies. Based on the above, we hypothesize that, as the technology of post transplant immunotherapy improves, the importance of MST and other protocols based on similar principles will grow, eventually becoming the treatment of choice.
